Home >Deals & Matter Corner>Deal>Proposed IPO of Senores Pharmaceuticals Limited

Proposed IPO of Senores Pharmaceuticals Limited

Deal
August 2, 2024

JSA is advising Equirus Capital Private Limited, Ambit Private Limited and Nuvama Wealth Management Limited (formerly known as Edelweiss Securities Limited) in relation to the proposed initial public offering of equity shares of Senores Pharmaceuticals Limited (“IPO”) comprising a fresh issue of up to INR 5 billion and an offer for sale aggregating up to 2,700,000 Equity Shares by certain Selling Shareholders. Senores Pharmaceuticals Limited has filed its draft red herring prospectus with SEBI on July 26, 2024.

Deal value: Fresh Issue of INR 5 billion and Offer for Sale of 2,700,000 Equity Shares

Our Transaction Team Comprised Lead Partner – Arka Mookerjee, Partner – Siddhartha Desai, Senior Associate – Akash Joshi, Associates – Govind Roy, Anvita Sinha, Reshmi Prabhakar and Ankesh Kumar.

POST TAGS

Tags JSA, Leading Law Firm, Leading Lawyers, Senores Pharmaceuticals Limited

Akash Joshi Senior Associate

Akash practices primarily in the area of capital markets and securities. He has advised clients on best possible drafting strategies for offer documents meant for initial public offers and qualified institutions placement.

Arka Mookerjee Partner

Arka’s practice area covers primarily equity capital markets issuances which covers a wide range of products such as Initial Public Offerings, Rights Issues, Qualified Institutions Placements, Initial Public Offering of Infrastructure Trusts and foreign currency convertible bonds.

Siddhartha Desai Partner

Siddhartha specializes in public and private Capital Market transactions. He has advised various issuers, underwriters and selling shareholders on equity offerings such as initial public offerings, rights issues, qualified institutions placements, institutional placement programmes & infrastructure investment trusts (InvITs), and debt offerings such as non-convertible debenture issuances.